JPWO2023080159A5 - - Google Patents
Info
- Publication number
- JPWO2023080159A5 JPWO2023080159A5 JP2023558051A JP2023558051A JPWO2023080159A5 JP WO2023080159 A5 JPWO2023080159 A5 JP WO2023080159A5 JP 2023558051 A JP2023558051 A JP 2023558051A JP 2023558051 A JP2023558051 A JP 2023558051A JP WO2023080159 A5 JPWO2023080159 A5 JP WO2023080159A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- ligand
- acc
- cha
- aib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021179771 | 2021-11-02 | ||
| PCT/JP2022/040996 WO2023080159A1 (ja) | 2021-11-02 | 2022-11-02 | リガンド結合核酸複合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023080159A1 JPWO2023080159A1 (https=) | 2023-05-11 |
| JPWO2023080159A5 true JPWO2023080159A5 (https=) | 2025-10-28 |
Family
ID=86241157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023558051A Pending JPWO2023080159A1 (https=) | 2021-11-02 | 2022-11-02 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4428238A1 (https=) |
| JP (1) | JPWO2023080159A1 (https=) |
| WO (1) | WO2023080159A1 (https=) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55113753A (en) | 1979-02-22 | 1980-09-02 | Toyo Jozo Co Ltd | Parathyroid hormone derivative |
| JP3781879B2 (ja) | 1996-11-18 | 2006-05-31 | 武 今西 | 新規ヌクレオチド類縁体 |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| JP2009536222A (ja) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｐｃｓｋ９の発現を調節するための化合物および方法 |
| WO2008029619A1 (fr) | 2006-09-07 | 2008-03-13 | Daiichi Sankyo Company, Limited | Oligonucléotide antisens ena ayant une action spécifique de la séquence |
| CA2666191C (en) | 2006-10-09 | 2017-07-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pcsk9 |
| ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| CN102753187A (zh) * | 2009-06-03 | 2012-10-24 | 戴瑟纳制药公司 | 肽-dicer底物试剂及其特异性抑制基因表达的方法 |
| JP6112569B2 (ja) | 2011-12-16 | 2017-04-12 | 国立大学法人 東京医科歯科大学 | キメラ２重鎖核酸 |
| WO2017131124A1 (ja) | 2016-01-26 | 2017-08-03 | 日産化学工業株式会社 | 一本鎖オリゴヌクレオチド |
| JPWO2018003739A1 (ja) | 2016-06-30 | 2019-04-18 | レナセラピューティクス株式会社 | 機能的リガンドを含む核酸複合体 |
| WO2018051762A1 (ja) * | 2016-09-14 | 2018-03-22 | レナセラピューティクス株式会社 | 副作用を減じたアンチセンス核酸 |
| WO2018140821A1 (en) * | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
| JP7479923B2 (ja) | 2020-05-13 | 2024-05-09 | Sansan株式会社 | 名刺情報処理装置、名刺情報処理方法、およびプログラム |
-
2022
- 2022-11-02 EP EP22889979.5A patent/EP4428238A1/en active Pending
- 2022-11-02 WO PCT/JP2022/040996 patent/WO2023080159A1/ja not_active Ceased
- 2022-11-02 JP JP2023558051A patent/JPWO2023080159A1/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2061382C (en) | Method for producing cysteine-free peptide | |
| US11944688B2 (en) | Biologically active compounds | |
| US11911443B2 (en) | Fusion proteins with extended serum half life | |
| TW202229323A (zh) | 新型glp-1/gip雙重促效劑 | |
| EP4389893A1 (en) | Human transferrin receptor binding peptide-drug conjugate | |
| AU2023203430A1 (en) | Novel glp-1 analogues | |
| JP2020172496A (ja) | 分枝状アミノ酸プローブを有するペプチド類似体 | |
| CA2226087A1 (en) | Nucleotide and protein sequences of vertebrate delta genes and methods based thereon | |
| JP2010516758A5 (https=) | ||
| TW201617373A (zh) | 胜肽載體上之多重寡核苷酸部分 | |
| CZ291212B6 (cs) | Hybridní protein, molekula DNA, expresní vektor, hostitelská buňka, způsob produkce hybridního proteinu, jeho pouľití a farmaceutický prostředek | |
| JPWO2023080159A5 (https=) | ||
| WO2020043750A9 (en) | Neoantigen engineering using splice modulating compounds | |
| JPH0632624B2 (ja) | 生長ホルモン放出因子ｇｒｆコ−ド構造遺伝子を含有する二本鎖ポリデオキシニユクレオチド | |
| IL298626A (en) | Cytokine conjugates | |
| US20050250185A1 (en) | OGH fusion polypeptides and therapeutic uses thereof | |
| WO2005058953A2 (en) | Ogh fusion polypeptides and therapeutic uses thereof | |
| WO1983004028A1 (en) | The manufacture and expression of genes for calcitonin and polypeptide analogs thereof | |
| EP2686343B1 (en) | Modified receptor fusion proteins | |
| EP4428238A1 (en) | Ligand-bound nucleic acid complex | |
| WO2025076243A1 (en) | Cell-targeting complexes and uses thereof | |
| JPH05103666A (ja) | ヒト神経成長因子を発現させるための方法 | |
| JP3352713B2 (ja) | ペプチドの製造法 | |
| EP4480964A1 (en) | Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases | |
| JPH06306100A (ja) | Ｖｉｐアナログ調製用融合蛋白、ｖｉｐアナログの製法並びにそのための遺伝子組換えプラスミド及び形質転換微生物 |